Filing Flows › Praxis Precision Medicines (PRAX) › Stock forecast & fair value
Praxis Precision Medicines (PRAX) stock forecast and fair value
Praxis Precision Medicines (PRAX) trades at $285.48. 21 analysts' median price target is $582.00 (+104%), from $188.00 to $1,201.00. Across 7 valuation methods the middle fair value is $33.53 (-88%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Residual income | $1.51 | $1.65 | $1.81 | -99% |
| Analysts' price targets | $188.00 | $650.00 | $1,201.00 | +128% |
| Tangible book (asset value) | $36.81 | $46.01 | $46.01 | -84% |
| Net cash (floor) | $23.44 | $26.04 | $26.04 | -91% |
| Stage-weighted value (pre-revenue) | $28.45 | $33.53 | $33.53 | -88% |
| Combined forecast (3 months) | $233.75 | $296.85 | $367.80 | +4% |
| Net current asset value (net-net) | $16.54 | $24.81 | $24.81 | -91% |
Praxis Precision Medicines' latest quarter
Praxis Precision Medicines, Q4 2024: revenue $7.5M (14× year over year), operating margin -857.0%, net loss $58.7M, operating cash flow −$56.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PRAX stock?
The median of 21 analysts' 12-month targets is $582.00, +104% from $285.48; the range is $188.00 to $1,201.00. The average rating is strong buy.
What is Praxis Precision Medicines' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $1.65 and $650.00, with a middle value of $33.53 against a price of $285.48. Each method's assumptions are on the page.
Does Praxis Precision Medicines usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is PRAX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.